טוען...
Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer
BACKGROUND: The accord 11/0402 trial demonstrated that folfirinox (5-fluorouracil, leucovorin, irinotecan, oxaliplatin) is significantly more efficacious than gemcitabine monotherapy in the first-line treatment of metastatic pancreatic cancer (mpc). The present study assessed the cost-effectiveness...
שמור ב:
| Main Authors: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Multimed Inc.
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3921047/ https://ncbi.nlm.nih.gov/pubmed/24523620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.21.1327 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|